Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform



Developer of RNA-based immunotherapeutics for cancer and viral diseases intended to harness one of the most essential pathways in the innate immune system. The company's RNA-based immunotherapeutics offers proprietary retinoic acid inducible gene I (RIG-I) activators for the treatment of cancer and is designed to initiate specific activation of multiple RIG-I pathways to kill tumor cells and to enable long-term immunity against the cancer associated with the tumor, enabling healthcare providers to generate effective therapies.

Ownership Status
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Other Industries
Drug Discovery
Parent Company
Primary Office
  • Izb, Am Klopferspitz 19
  • Planegg/Martinsried
  • 82152 Munich
  • Germany

+49 089 000000000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Rigontec’s full profile, request a free trial.

Rigontec Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Merger/Acquisition 26-Oct-2017 $551M 000.00 00000 Completed Generating Revenue
2. Early Stage VC (Series A) 06-Sep-2016 000.00 000.00 Completed Startup
1. Accelerator/Incubator Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Rigontec Competitors (38)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Gadeta Venture Capital-Backed Utrecht, Netherlands 00.000 00000000000 00.000
000000000 Venture Capital-Backed Rockville, MD 000.00 0000000000 0 000.00
000000000000 Venture Capital-Backed Houston, TX 000.00 00000000000 000.00
00000000 Venture Capital-Backed Tübingen, Germany 000 00000 00000000000 00000
0000000 0000000000 Formerly VC-backed Watertown, MA 00 00000 000000000 00000
To view this company’s complete list of competitors, request access »

Rigontec Former Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Boehringer Ingelheim Venture Fund Corporate Venture Capital Minority 000 0000 000000 0
Forbion Venture Capital Minority 000 0000 000000 0
German Accelerator Accelerator/Incubator 000 0000 000000 0
High-Tech Gründerfonds Venture Capital Minority 000 0000 000000 0
MP Healthcare Venture Management Corporate Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 8 investors. Get the full list »

Rigontec Executive Team (10)

Name Title Board
Christian Schetter Ph.D Chief Executive Officer & Board Member
Christine Schuberth-Wagner Ph.D Co-Founder, Senior Vice President of Research, Chief Operating Officer & Chief Scientific Officer
Frank Hennecke Ph.D Executive Vice President of Manufacturing & Control
Marcel Renn Ph.D Head, Biology & Co-Founder
Anna Schwickart Ph.D Head, CMC & Preclinical Project Management & Co-Founder

1 Former Executive

You’re viewing 5 of 10 executives. Get the full list »

Rigontec Board Members (7)

Name Representing Role Since Contact
Christian Schetter Ph.D Rigontec Chief Executive Officer & Board Member 000 0000
Donald DeBethizy Ph.D Rigontec Chairman 000 0000
Gunther Hartmann Self Advisor, Board Member & Co-Founder 000 0000

4 Former Board Members

You’re viewing 3 of 7 board members. Get the full list »